Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Becaplermin gel - Johnson & Johnson

Drug Profile

Becaplermin gel - Johnson & Johnson

Alternative Names: PGDF-B; Recombinant human platelet-derived growth factor-beta; Regranex; RWJ 60235

Latest Information Update: 28 Sep 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson; ZymoGenetics
  • Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
  • Mechanism of Action Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic foot ulcer
  • Discontinued Pressure ulcer; Varicose ulcer

Most Recent Events

  • 25 Sep 2013 Healthpoint Biotherapeutics is now called Smith & Nephew Biotherapeutics
  • 21 Dec 2012 Healthpoint Biotherapeutics has been acquired by Smith & Nephew
  • 03 Jun 2011 Healthpoint Biotherapeutics acquires becaplermin gel from Systagenix Wound Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top